Skip to content
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Oncology

What Are the Side Effects of Rituximab Maintenance?

At a Glance

Rituximab maintenance for follicular lymphoma extends remission but suppresses the immune system. The main side effects are a higher risk of infections, low antibody levels, delayed drops in white blood cells (neutropenia), and reduced effectiveness of standard vaccines like the flu shot.

You will not have to stay on rituximab maintenance forever. Standard maintenance therapy for follicular lymphoma is typically given for up to two years [1][2]. Its primary purpose is to keep your disease in remission longer. However, because it continuously suppresses a part of your immune system, it carries risks such as increased susceptibility to infections, low antibody levels (hypogammaglobulinemia), and late drops in white blood cell counts (late-onset neutropenia) [1][3].

The Goal, Timeline, and Logistics of Maintenance Therapy

After you successfully complete your initial treatment (induction therapy) and your lymphoma is in remission, your doctor may recommend rituximab maintenance. While being in remission is wonderful news, acknowledging that you still have to visit the cancer center regularly for two years can feel like a heavy emotional and logistical burden.

  • Duration: It is generally administered once every 8 weeks for up to two years [1].
  • Administration: Maintenance can be given as a traditional intravenous (IV) infusion at the cancer center or, in some cases, as a much faster subcutaneous injection (a shot under the skin), which significantly shortens your time in the clinic [4][5].
  • Purpose: The goal is to extend your progression-free survival—the length of time you live without the disease returning or worsening. Studies show that two years of maintenance significantly delays the need for further chemotherapy [1][6].
  • Overall Survival: While it keeps the lymphoma away longer, studies show that patients who receive maintenance live roughly the same total amount of time as those who do not (overall survival) [1].

Because it does not extend your total lifespan, the decision to complete the full two years of maintenance is a balance between enjoying a longer remission and managing the side effects of prolonged immune suppression.

Key Side Effects to Watch For

Rituximab works by targeting and depleting B-cells, a type of white blood cell involved in your lymphoma. However, because healthy B-cells are responsible for producing immunoglobulins (antibodies) that fight off illnesses, depleting them leaves your immune system compromised [7][3].

Increased Risk of Infections

The most common side effect of extended rituximab use is a higher risk of infections, such as colds, sinus infections, or bronchitis [8][9]. Your care team will monitor you closely, and you should report any signs of infection (like a fever, cough, or sore throat) immediately.

Hypogammaglobulinemia (Low Antibodies)

Because rituximab keeps your B-cell count low for two years, your overall antibody levels can drop, a condition called hypogammaglobulinemia [7].

  • This makes it harder for your body to fight off recurrent infections.
  • Your doctor can check your immunoglobulin levels through a simple blood draw (often done right before your maintenance infusion).
  • If your levels become dangerously low and you are getting frequent infections, your doctor might recommend stopping the rituximab or giving you immunoglobulin replacement therapy (IgRT) to temporarily boost your antibodies [10][11].

Late-Onset Neutropenia

Neutrophils are a different type of white blood cell that acts as a first responder to bacterial infections. Late-onset neutropenia is a sudden drop in these cells that can happen months after you start or even finish rituximab therapy [12][3].

  • It happens in roughly 6% of patients receiving this treatment [12].
  • Often, it causes no symptoms and resolves on its own without needing specific treatment [13][14].
  • Because low neutrophils leave you vulnerable to severe infections, your care team will continue monitoring your complete blood counts (CBC) throughout your maintenance period, typically via a blood draw before each treatment [15].

Reduced Vaccine Effectiveness

Because your B-cells are depleted and cannot efficiently produce antibodies, standard vaccines (like the flu, COVID-19, or RSV vaccines) will not work as well while you are on maintenance therapy [16][17]. Although your immune system may still mount a partial defense using other immune cells, you should consult your care team about the optimal timing for vaccines. Furthermore, you must avoid “live” vaccines (like the yellow fever or oral polio vaccines) while you are immunocompromised.

Daily Precautions

While on maintenance therapy, taking practical steps can help you live safely:

  • Avoid sick contacts: Steer clear of crowds and people who are visibly ill.
  • Practice good hygiene: Wash hands frequently and carry hand sanitizer.
  • Masking: Consider wearing a high-quality mask (like an N95) when in crowded indoor spaces or during peak cold and flu seasons.
  • Food safety: Ensure your food is properly cooked and avoid unpasteurized dairy products to minimize exposure to foodborne bacteria.

If the side effects, emotional toll, or infection risks ever outweigh the benefits, you and your doctor can decide to stop maintenance therapy early.

Common questions in this guide

How long do you stay on rituximab maintenance for follicular lymphoma?
Standard rituximab maintenance therapy is typically given once every eight weeks for up to two years. Its main goal is to keep your lymphoma in remission longer by delaying the return of the disease, though it does not typically extend overall total lifespan.
What is the most common side effect of rituximab maintenance?
The most common side effect is an increased risk of infections, such as colds, sinus infections, or bronchitis. This happens because the drug depletes B-cells, lowering your body's ability to produce the antibodies needed to fight off illnesses.
Why are my antibody levels checked during maintenance therapy?
Rituximab can cause your overall antibody levels to drop, a condition called hypogammaglobulinemia. If your levels become too low and you experience frequent infections, your doctor may suggest immunoglobulin replacement therapy (IgRT) to temporarily boost your immune system.
Can I get standard vaccines while on rituximab maintenance?
While you can receive standard non-live vaccines like the flu or COVID-19 shots, they may be less effective because your B-cells are depleted. You must completely avoid live vaccines and should consult your care team about the best timing for any immunizations.
Is rituximab maintenance given through an IV or an injection?
Maintenance therapy can be given as a traditional intravenous (IV) infusion at the cancer center or as a faster subcutaneous injection under the skin. You can ask your doctor if you are a candidate for the quicker injection option to help shorten your clinic visits.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Am I a candidate for the faster subcutaneous (under-the-skin) injection, or do I need the IV infusion?
  2. 2.Should I get my seasonal vaccines (like the flu or COVID-19 shot) before I start maintenance, or is there a specific timing you recommend?
  3. 3.What temperature of fever requires an immediate call to the clinic or an emergency room visit?
  4. 4.If I get frequent respiratory infections on maintenance, at what point would we consider checking my antibodies or starting immunoglobulin replacement therapy (IgRT)?
  5. 5.Given my age, health, and previous treatments, do you feel the benefits of a longer remission outweigh the risk of prolonged immune suppression for me?
  6. 6.Should my family members update their vaccines to help protect me while my immune system is suppressed?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (17)
  1. 1

    Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study.

    Bachy E, Seymour JF, Feugier P, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019; (37(31)):2815-2824 doi:10.1200/JCO.19.01073.

    PMID: 31339826
  2. 2

    Rituximab Maintenance Versus Observation After Immunochemotherapy (R-CHOP, R-MCP, and R-FCM) in Untreated Follicular Lymphoma Patients: A Randomized Trial of the Ostdeutsche Studiengruppe Hämatologie und Onkologie and the German Low-Grade Lymphoma Study Group.

    Hirt C, Hoster E, Unterhalt M, et al.

    HemaSphere 2021; (5(7)):e600 doi:10.1097/HS9.0000000000000600.

    PMID: 34179697
  3. 3

    Hypogammaglobulinemia, late-onset neutropenia, and infections following rituximab.

    Athni TS, Barmettler S

    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2023; (130(6)):699-712 doi:10.1016/j.anai.2023.01.018.

    PMID: 36706910
  4. 4

    Clinical efficacy and safety of subcutaneous rituximab in non-Hodgkin lymphoma: a systematic literature review and meta-analysis.

    Si T, Ma X, Zhu W, Zhou Y

    Hematology (Amsterdam, Netherlands) 2023; (28(1)):2284047 doi:10.1080/16078454.2023.2284047.

    PMID: 38010876
  5. 5

    Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial.

    Davies A, Merli F, Mihaljević B, et al.

    The Lancet. Haematology 2017; (4(6)):e272-e282 doi:10.1016/S2352-3026(17)30078-9.

    PMID: 28476440
  6. 6

    Efficacy and safety assessment of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results of the phase III MabCute study.

    Rule S, Barreto WG, Briones J, et al.

    Haematologica 2022; (107(2)):500-509 doi:10.3324/haematol.2020.274803.

    PMID: 34134469
  7. 7

    Hypogammaglobulinemia after front-line immunochemotherapy in patients with follicular lymphoma.

    Díaz Acedo R, Artacho Criado S, Ríos Herranz E, et al.

    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2023; (29(8)):1982-1989 doi:10.1177/10781552231162540.

    PMID: 36908267
  8. 8

    The Outcome of SARS-CoV-2 Infection in Patients with Lymphoma and the Risk Factors for the Development of Pneumonia.

    Hong H, Choi SM, Jeon YW, et al.

    Infection & chemotherapy 2024; (56(3)):378-385 doi:10.3947/ic.2024.0046.

    PMID: 39370123
  9. 9

    Long-Term Outcomes of COVID-19 and Risk Factors for Prolonged or Persistent COVID-19 in Lymphoma Patients: A Multicenter, Retrospective Cohort Study.

    Lee JA, Han M, Ahn S, et al.

    Journal of Korean medical science 2024; (39(41)):e263 doi:10.3346/jkms.2024.39.e263.

    PMID: 39468945
  10. 10

    Recommendations for Management of Secondary Antibody Deficiency in Multiple Myeloma.

    Giralt S, Jolles S, Kerre T, et al.

    Clinical lymphoma, myeloma & leukemia 2023; (23(10)):719-732 doi:10.1016/j.clml.2023.05.008.

    PMID: 37353432
  11. 11

    Rational use of immunoglobulins (IVIgs and SCIgs) in secondary antibody deficiencies.

    Goede JS, Baumann CK, Cathomas R, et al.

    Swiss medical weekly 2024; (154()):3559 doi:10.57187/s.3559.

    PMID: 39462479
  12. 12

    Incidence, Clinical Features, and Outcomes of Late-Onset Neutropenia From Rituximab for Autoimmune Disease.

    Zonozi R, Wallace ZS, Laliberte K, et al.

    Arthritis & rheumatology (Hoboken, N.J.) 2021; (73(2)):347-354 doi:10.1002/art.41501.

    PMID: 32892495
  13. 13

    Late-Onset Neutropenia After Rituximab-Containing Therapy for Non-Hodgkin Lymphoma.

    Aguiar-Bujanda D, Blanco-Sánchez MJ, Hernández-Sosa M, et al.

    Clinical lymphoma, myeloma & leukemia 2015; (15(12)):761-5.

    PMID: 26319620
  14. 14

    Rituximab associated late-onset neutropenia-a rheumatology case series and review of the literature.

    Monaco WE, Jones JD, Rigby WF

    Clinical rheumatology 2016; (35(10)):2457-62 doi:10.1007/s10067-016-3313-y.

    PMID: 27209045
  15. 15

    Rituximab-mediated late onset neutropenia in autoimmune blistering diseases: negligible or under-estimated threat?

    Hosp C, Goebeler M, Benoit S, Stoevesandt J

    Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2020; (18(10)):1162-1164 doi:10.1111/ddg.14159.

    PMID: 32656964
  16. 16

    B Cell Numbers Predict Humoral and Cellular Response Upon SARS-CoV-2 Vaccination Among Patients Treated With Rituximab.

    Stefanski AL, Rincon-Arevalo H, Schrezenmeier E, et al.

    Arthritis & rheumatology (Hoboken, N.J.) 2022; (74(6)):934-947 doi:10.1002/art.42060.

    PMID: 34962360
  17. 17

    Humoral immune response following SARS-CoV-2 mRNA vaccination concomitant to anti-CD20 therapy in multiple sclerosis.

    Novak F, Nilsson AC, Nielsen C, et al.

    Multiple sclerosis and related disorders 2021; (56()):103251 doi:10.1016/j.msard.2021.103251.

    PMID: 34571415

This page is for informational purposes only and does not replace professional medical advice. Always consult your oncologist about managing side effects and infection risks during rituximab maintenance.

Get notified when new evidence is published on Follicular lymphoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.